EVOK — Evoke Pharma Share News
0.000.00%
Last trade - 00:00- $18.86m
- $12.28m
- $10.25m
Evoke Pharma Inc reports results for the quarter ended in March - Earnings Summary
Brief: Evoke Pharma Reports First Quarter 2023 Financial Results
Evoke Pharma Inc expected to post a loss of 58 cents a share - Earnings Preview
Evoke Pharma Inc expected to post a loss of 58 cents a share - Earnings Preview
Brief: United States Patent And Trademark Office (USPTO) Grants Evoke Pharma A Formulation Patent Covering Gimoti
Brief: Evoke Pharma Receives Notice Of Allowance From USPTO For GIMOTI-Related Patent
Evoke Pharma Inc reports results for the quarter ended in December - Earnings Summary
Brief: Evoke Pharma Reports Fourth Quarter Financial Results
Evoke Pharma Inc expected to post a loss of 53 cents a share - Earnings Preview
Evoke Pharma Inc expected to post a loss of 53 cents a share - Earnings Preview
Brief: Evoke Announces Teva Ends Pursuit Of Paragraph IV ANDA Against Gimoti
Evoke Pharma rises on new patent for nasal spray
U.S. STOCKS ON THE MOVE-Gold miners, silver miners, Solaredge Technologies
U.S. STOCKS ON THE MOVE-Uniti Group, Pfizer, Moleculin Biotech
Evoke Pharma rises on new patent for nasal spray
Brief: Uspto Grants New Patent To Evoke Pharma Covering Usage Of Gimoti® To Treat Moderate To Severe Gastroparesis
Brief: Evoke Pharma Strengthens Its Intellectual Property Portfolio With A Notice Of Allowance From The Uspto For A Patent Application Related To Gimoti®
Evoke Pharma Inc reports results for the quarter ended in September - Earnings Summary
Brief: Evoke Pharma Reports Record Third Quarter 2022 Financial Results